CIK 0001720580 · Non-accelerated filer<br>Smaller reporting company
Adicet Bio, Inc.
Sign in to watch- Ticker
- ACET
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 26
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813305277
- Phone
- 617-482-2333
- Business address
- 131 DARTMOUTH STREET, 3RD FLOOR, BOSTON, MA, 02116
- Former names
- resTORbio, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-31 | Aftab Blake Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +275,000 | 275,000 | ||
| 2025-01-31 | Schor Chen President & CEO | Grant or award · Stock Option (Right to Buy) | +763,829 | 763,829 | ||
| 2025-01-31 | Healey Don Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +275,000 | 275,000 | ||
| 2025-01-31 | Maltzman Julia D. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +750,000 | 750,000 | ||
| 2025-01-31 | Harvey Brian Nicholas Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +324,040 | 324,040 | ||
| 2025-01-24 | Schor Chen President & CEO | Shares withheld for taxes | −28,101 | $0.92 | $26K | 137,201 |
| 2025-01-24 | Healey Don Chief Technology Officer | Shares withheld for taxes | −8,560 | $0.92 | $8K | 63,769 |
| 2025-01-24 | Aftab Blake Chief Scientific Officer | Shares withheld for taxes | −6,270 | $0.92 | $6K | 56,241 |
| 2025-01-24 | Harvey Brian Nicholas Chief Financial Officer | Shares withheld for taxes | −8,752 | $0.92 | $8K | 91,048 |
| 2024-08-21 | Sinclair Andrew Director | Returned to the company · Stock Option (Right to Buy) | −28,828 | 0 | ||
| 2024-08-21 | Sinclair Andrew Director | Grant or award · Stock Option (Right to Buy) | +28,828 | 28,828 | ||
| 2024-08-21 | Sinclair Andrew Director | Returned to the company · Stock Option (Right to Buy) | −18,500 | 0 | ||
| 2024-08-21 | Sinclair Andrew Director | Grant or award · Stock Option (Right to Buy) | +18,500 | 18,500 | ||
| 2024-08-21 | Sinclair Andrew Director | Returned to the company · Stock Option (Right to Buy) | −8,172 | 0 | ||
| 2024-08-21 | Sinclair Andrew Director | Grant or award · Stock Option (Right to Buy) | +8,172 | 8,172 | ||
| 2024-08-21 | Sinclair Andrew Director | Returned to the company · Stock Option (Right to Buy) | −18,500 | 0 | ||
| 2024-08-21 | Sinclair Andrew Director | Grant or award · Stock Option (Right to Buy) | +18,500 | 18,500 | ||
| 2024-08-21 | Sinclair Andrew Director | Returned to the company · Stock Option (Right to Buy) | −26,400 | 0 | ||
| 2024-08-21 | Sinclair Andrew Director | Grant or award · Stock Option (Right to Buy) | +26,400 | 26,400 | ||
| 2024-08-21 | GORDON CARL L Director | Returned to the company · Stock Option (Right to Buy) | −30,000 | 0 |
Page 3 of 15 · 298 trades